Genotypic tropism testing: Evidence-based or leap of faith?

AIDS

Volumn 25, Issue 2, 2011, Pages 257-264

  Harrigan, P Richard ^a   Geretti, Anna Maria ^b  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

genotype; gp120; HIV 1; tropism; V3 loop

Indexed keywords

ABACAVIR; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; MARAVIROC; NEVIRAPINE; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VICRIVIROC; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

AMINO ACID SEQUENCE; DIAGNOSTIC TEST; DRUG ACTIVITY; DRUG TOLERABILITY; GENOTYPIC TROPISM TESTING; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MEDICAL PRACTICE; NONHUMAN; NOTE; POST HOC ANALYSIS; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CONTROLLED CLINICAL TRIALS AS TOPIC; GENOTYPE; HIV-1; HUMANS; VIRAL ENVELOPE PROTEINS; VIRAL TROPISM;

EID: 78650875956     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834113f9     Document Type: Note

References (50)

1. Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore JP, et al. A new classification for HIV-1. Nature 1998; 391:240.
2. Moyle GJ, Wildfire A, Mandalia S, Mayer H, Goodrich J, Whitcomb J, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191:866-872.
3. Soriano V, Perno CF, Kaiser R, Calvez V, Gatell JM, di Perri G, et al. When and how to use maraviroc in HIV-infected patients. AIDS 2009; 23:2377-2385.
4. Gathe J, Diaz R, Fatkenheuer G, Zeinecker J, Mak C, Vilchez R, et al. Phase 3 trials of vicriviroc in treatment-experienced subjects demonstrate safety but not significantly superior efficacy over potent background regimens alone. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, 16-19 February 2010 [abstract 54LB].
5. Dunkle LM. Vicriviroc discontinued investigator letter. July 9 2010. Available at http://www.natap.org/2010/newsUpdates/ 071510-02.htm. [Accessed September 2010]
6. Palleja S, Cohen C, Gathe J, Thompson M, DeJesus E, Brinson C, et al. Safety and efficacyof TBR 652, a CCR5 antagonist, in HIV-1-infected, ART-experienced, CCR5 antagonist-näve patients. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, 16-19 February 2010 [abstract 53].
7. Martin DE, Palleja1 S, Gathe J, Thompson M, Cohen C, De Jesus E, et al. TBR-652, a potent dual chemokine receptor 5/chemo-kine receptor 2(CCR5/CCR2) antagonist in phase 2 development for treatment of HIV infection. 18th International AIDS Conference, Vienna, 18-23 July 2010 [abstract MOAB0104].
8. Jacobson JM, Thompson MA, Lalezari JP, Saag MS, Zingman BS, D'Ambrosio P, et al. Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J Infect Dis 2010; 201:1481-1487.
9. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, et al. Maraviroc for previously treatment patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-1441.
10. Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359:1442-1455.
11. Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, Dejesus E, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of anti-retroviral-näve subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010; 201:803-813.
12. Saag M, Goodrich J, Fätkenheuer G, Clotet B, Clumeck N, Sullivan J, et al. A double-blind, placebo controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 2009; 199:1638-1647.
13. Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS Clinical Trials Group 5211. J Infect Dis 2007; 196:304-312.
14. Suleiman J, Zingman BS, Diaz RS, Madruga JV, DeJesus E, Slim J, et al. Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial. J Infect Dis 2010; 201:590-599.
15. Su Z, Gulick R, Krambrink A, Coakley E, Hughes MD, Han D, et al. Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J Infect Dis 2009; 200:1724-1728.
16. Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51:566-575.
17. Reeves JD, Coakley E, Petropoulos CJ, Whitcomb JM. An en-hanced-sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J Viral Entry 2009; 3:94-102.
18. Strizki JM, McNicholas P, Mann P, Wojcik L, Qiu P, Shen J, et al. Use of the enhanced sensitivity tropism assay (ESTA) to predict on-treatment detection of CXCR4-using virus and impact on virological outcomes in a vicriviroc (VCV) Phase II treatment-experienced study (Victor-E1) [Abstract]. Antivir Ther 2010; 15 (Suppl 2):A18.
19. Saag M, Heera J, Goodrich J, DeJesus E, Clumeck N, Cooper D, et al. Reanalysis of the MERIT study with the enhanced Trofile assay. 48th ICAAC Annual/46th IDSA Annual Meeting, Washington, 25-28 October 2008 [abstract H-1269].
20. Strang AL, Cameron J, Booth C, Garcia-Diaz AM, Geretti AM. Genotypic prediction of viral co-receptor tropism: correlation with enhanced Trofile [Abstract]. HIV Med 2009; 10 (Suppl 1): 42.
21. Toma J, Frantzell A, Hoh R, Martin J, Deeks S, Petropoulos C, et al. Determining HIV-1 coreceptor tropism using PBMC proviral DNA derived from aviremic blood samples. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, 16-19 February 2010 [abstract 541].
22. Beerenwinkel N, Däumer M, Oette M, Korn K, Hoffmann D, Kaiser R, et al. Geno2pheno: estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res 2003; 31:3850-3855.
23. Jensen MA, LiFS, van'tWout AB, Nickle DC, ShrinerD,He HX, et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003; 77:13376-13388.
24. Low AJ, Marchant D, Brumme CJ, Brumme ZL, Dong W, Sing T, et al. CD4-dependent characteristics of co-receptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals. AIDS Res Human Retroviruses 2008; 24:219-228.
25. Sing T, Low AJ, Beerenwinkel N, Sander O, Cheung PK, Dom-ingues FS, et al. Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther 2007; 12:1097-1106.
26. Prosperi MC, Bracciale L, Fabbiani M, Di Giambenedetto S, Razzolini F, Meini G, et al. Comparative determination of HIV-1 co-receptor tropism by enhanced sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping. Retrovirol 2010; 30:56.
27. Soulie C, Fourati S, Lambert-Niclot S, Malet I, Wirden M, Tubiana R, et al. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV load: implications for the clinical use of CCR5 antagonists. J Antimicrob Chemother 2010; 65:749-751.
28. Verhofstede C, Vandekerckhove L, Eygen VV, Demecheleer E, Vandenbroucke I, Winters B, et al. CXCR4-using HIV Type 1 variants are more commonly found in peripheral blood mono-nuclear cell DNA than in plasma RNA. J Acquir Immune Def Synd 2009; 50:126-136.
29. Macartney MJ, Cameron J, Strang AL, Garcia A, Booth C, Marshall N, et al. Use of a genotypic assay for prediction of HIV-1 co-receptor tropism and guiding the use of CCR5 antagonists in clinical practice. 8th European HIV Drug Resistance Workshop, Sorrento, 17-19 March 2010 [abstract 44].
30. Obermeier MJ, Carganico A, Bieniek B, Cordes C, Dupke S, Fisher K, et al. Genotypic tropism testing from proviral DNA: test characteristics and clinical outcome [abstract]. Antivir Ther 2010; 15 (Suppl 2):A132.
31. Low AJ, Dong W, Chan D, Sing T, SwanstromR, Jensen M, et al. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 2007; 21:F17-F24.
32. Poveda E, Seclén E, González M, Garća F, Chueca N, Aguilera A, et al. Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J Antimicrob Chemother 2009; 63:1006-1010.
33. Swenson L, Moores A, Low A, Thielen A, Dong W, Woods C, et al. Improved detection of CXCR4-using HIV by V3 genotyp-ing: application of population-based and 'deep' sequencing to plasma RNA and proviral DNA. J Acquir Immune Def Synd 2010; 54:506-510.
34. Sanchez V, Robeldano C, Ciprian D, Montolio F, Escalano C, Padeilla S, et al. Evaluation of genotypic algorithms to predict HIV-1 coreceptor usage using Enhanced Sensitivity Trofile HIV coreceptor tropism assay [abstract]. HIV Med 2009; 10 (Suppl 2):49.
35. McGovern RA, ThielenA, Mo T, DongW,Woods CK, Chapman D, et al. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 2010; 24:2517-2525.
36. McGovernR,Dong W, ZhongX,KnappD,ThielenA, Chapman D, et al. Population-based sequencing of the V3-loop is comparable to the Enhanced Sensitivity Trofile Assay in predicting virologic response to maraviroc of treatment-näve patients in the MERIT trial. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, 16-19 February 2010 [abstract 92].
37. Obermeier MJ, Carganico A, Bieniek B, Cordes C, Dupke S, Golz J, et al. Update on the Berlin maraviroc cohort: genotypic tropism testing results and therapeutic outcome at weeks 12 and 24 [abstract]. HIV Med 2009; 10 (Suppl 2):67.
38. German recommendations for determining HIV-1 coreceptor usage. Available at http://www.viro.med.uni-erlangen.de/nrz/ recommendation080324.pdf. [Accessed Sept 2010]
39. Geretti AM, Mackie N. British HIV Association guidelines on determining HIV-1 tropism in routine clinical practice. Available at http://www.bhiva.org/ Tropism.aspx. [Accessed Jul 2010]
40. Vandekerckhove L, Wensing AMJ, Kaiser R, Brun-Vezinet F, Clotet B, De Luca A, et al. European consensus on clinical use and interpretation of HIV-1 tropism testing [Abstract]. HIV Med 2009; 10 (Suppl 2):48-49.
41. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell tropic virus population. J Virol 1992; 66:1354-1360.
42. Harrigan PR, McGovern R, Dong W, Mo T, Zhong X, Chapman D, et al. Optimization of clinically relevant cut-points for the determination of HIV co-receptor usage to predict maraviroc responses in treatment-experienced (TE) patients using population V3 genotyping [Abstract]. HIV Med 2009; 10 (Suppl 2):71.
43. Harrigan PR, MOTIVATE Tropism Study Group. Optimisation of clinically relevant cutoffs for determining HIV co-receptor use by population and 'deep' sequencing methods. 47th IDSA, Philadelphia, 29 October-1 November 2009 [abstract 297].
44. Waters L, Scourfield A, Marcano M, Gazzard B, Nelson M. The evolution of co-receptor tropism in patients interrupting sup-pressive HAART. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, 8-11 February 2009 [abstract 439a].
45. Seclén E, Del Mar González M, De Mendoza C, Soriano V, Poveda E. Dynamics of HIV tropism under suppressive anti-retroviral therapy: implications for tropism testing in subjects with undetectable viraemia. J Antimicrob Chemother 2010; 65:1493-1496.
46. Van T Wout AB, Swenson L, Welkers MRA, Dong W, Schuite-maker H, Harrigan PR. Detection of CXCR4-using HIV-1 variants in longitudinally obtained paired plasma and PBMC samples using 454-sequencing [Abstract]. Antivir Ther 2009; 14 (Suppl 1):A88.
47. Däumer MP, Kaiser R, Klein R, Lengauer T, Thiele B, Thielen A. Inferring viral tropism from genotype with massively parallel sequencing: qualitative and quantitative analysis [Abstract]. Antivir Ther 2008; 13 (Suppl 3):A101.
48. SwensonL,Dong W,MoT, WoodsC,ThielenA,JensenM,et al. Quantification of HIV tropism by 'deep' sequencing shows a broad distribution of prevalence of X4 variants in clinical samples that is associated with virological outcome. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, 8-11 February 2009 [abstract 680].
49. Ghezzi S, Menzo S, Brambilla A, Bordignon PP, Lorini AL, Clementi M, et al. Inhibition of R5X4 dualtropic HIV-1 primary isolates by single chemokine co-receptor ligands. Virology 2001; 280:253-261.
50. Lengauer T. Genotypic basis of viral tropism [invited lecture]. 4th International Workshop on Targeting HIV Entry, Rio Grande, 8-9 December 2008.